Curemark Appoints Preeminent Pediatrics Gastroenterologist

Wednesday, December 19, 2007 General News J E 4
RYE, N.Y., Dec. 18 Curemark's Board of Directors announcedtoday that Steven M. Schwarz, MD, FAAP, FACN, AGAF, will join the company as asenior scientist and will serve on the company's Scientific Advisory Board.Dr. Schwarz is presently Chairman of the Department of Pediatrics at The LongIsland College Hospital and Professor of Pediatrics at the State University ofNew York Health Science Center at Brooklyn.

"Dr. Schwartz is one of America's foremost authorities on pediatricgastroenterology," states Dr. Joan Fallon, Curemark's CEO. "Having Dr. Schwarzas an integral part of Curemark will assist the company greatly as we preparefor autism clinical trials scheduled for the early part of 2008. His vastexpertise in the areas of gastroenterology and developmental disabilities is aperfect fit with Curemark's research and proprietary work in pediatricdysautonomia, autism and ADHD."

A graduate of Yale College and Columbia University's College of Physiciansand Surgeons, Dr. Schwarz received his training in Pediatrics and PediatricGastroenterology and Nutrition at Columbia and Stanford Universities. Dr.Schwarz served on the faculty of the Children's Hospital of Philadelphia,University of Pennsylvania School of Medicine from 1980-84, and at New YorkMedical College from 1984-95. At New York Medical College, he was awarded theCharles H. Revson Foundation Career Scientist Award. In 1995 he was namedDistinguished Lecturer in the Graduate School of Health Sciences.

Curemark, with offices in Rye, NY, is a drug development company focusedon the treatment of neurological and other diseases by addressing certain keygastrointestinal/pancreatic secretory deficiencies. The company's initialproducts are based upon breakthrough observations by its founder, Dr. JoanFallon, which revealed a lack of key enzymes in autistic children. She hasidentified and patented a series of biomarkers that delineate which autisticpatients may have digestive deficiencies underlying their disease. Curemark isthe first company to deliver upon the connection between a variety ofconditions, including autism, ADD/ADHD, Parkinson's and others that have rootsin the gastrointestinal tract. To learn more about our innovative science,visit

This release was issued through eReleases(TM). For more information,visit Contact: Kate Taylor 914-925-3450 Investment Contact: Ken Nanus 914-450-0816

SOURCE Curemark


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
GeneGo Integrates With Cytoscape
Sidney Taurel to Retire as Lilly CEO; John Lechlei...